Table 2 Subgroup analyses of deaths
From: Treatment outcomes of tuberculous meningitis in adults: a systematic review and meta-analysis
Number of studies | Number of deaths | Number of patients assessed | Proportion of death (95%CI) | Heterogeneity (95%CI) | |
|---|---|---|---|---|---|
Study type | |||||
Prospective cohort | 9 | 322 | 1141 | 22.4%(14.1–33.8) | 3.4(2.7–4.4) |
Retrospective cohort | 11 | 205 | 983 | 22.0%(14.5–31.8) | 3.1(2.5–4.0) |
BMRC stage | |||||
Stage I | 7 | 60 | 356 | 17.5%(8.9–31.7) | 1.8(1.2–2.7) |
Stage II | 7 | 157 | 513 | 28.5%(20.6–37.9) | 1.7(1.2–2.6) |
Stage III | 7 | 207 | 318 | 64.8%(51.5–76.1) | 1.9(1.3–2.8) |
HIV infection | |||||
HIV positive | 7 | 301 | 547 | 53.4%(42.4–64.1) | 2.1(1.4–3.0) |
HIV negative | 11 | 257 | 1264 | 17.5%(12.1–24.7) | 2.7(2.1–3.5) |
Treatment duration | |||||
At least 6 months | 9 | 256 | 853 | 27.9%(19.7–38.8) | 3.1(2.4–4.0) |
At least 9 months | 13 | 498 | 1584 | 22.4%(14.5–32.8) | 4.0(3.4–4.8) |
Treatment with streptomycin | |||||
Yes | 5 | 102 | 558 | 17.1(8.5–31.6) | 3.5(2.5–4.9) |
No | 11 | 181 | 783 | 20.3%(13.6–29.2) | 2.6(2.0–3.3) |